Immunotherapy and lung cancer: Current developments and novel targeted therapies

Immunotherapy

Volumn 6, Issue 11, 2014, Pages 1221-1235

  Domingues, Duarte ^a,b   Turner, Alice ^c   Silva, Maria Dília ^b   Marques, Dânia Sofia ^a   Mellidez, Juan Carlos ^b   Wannesson, Luciano ^d   Mountzios, Giannis ^e   De Mello, Ramon Andrade ^a,f  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Hospital Infante D Pedro EPE   (Portugal)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

checkpoint inhibitors; immunotherapies; lung cancer; nivolumab; tremelimumab; tumor vaccines

Indexed keywords

CANCER ANTIBODY; DENDRITIC CELL VACCINE; IMMUNOMODULATING AGENT; IPILIMUMAB; LIRILUMAB; MELANOMA ANTIGEN 3; NIVOLUMAB; PEMBROLIZUMAB; RECOMBINANT CYTOKINE; TECEMOTIDE; TG 4010; TICILIMUMAB; TUMOR CELL VACCINE; CANCER VACCINE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOKINE INDUCED KILLER CELL; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; METASTASIS; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; TREATMENT OUTCOME; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNITY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS;

EID: 84919832561     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.82     Document Type: Review

References (72)

1. GLOBOCAN. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin. Proc. 83(3), 355-367 (2008
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83(5), 584-594 (2008
4. National Institutes of Health. Cancer of the Lung and Bronchus - SEER Stat Fact Sheet. http://seer.cancer.gov/statfacts/html/lungb.html
5. Scagliotti G, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008
6. Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-360 (2004
7. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin. Cancer Res. 15(16), 5267-5273 (2009
8. Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: A review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 20(1), 22-31 (2013
9. McCarthy F, Roshani R, Steele J, Hagemann T. Current clinical immunotherapy targets in advanced non-small cell lung cancer (NSCLC). J. Leukoc. Biol. 94(6), 1201-1206 (2013
10. Iyengar P, Gerber DE. Locally advanced lung cancer: An optimal setting for vaccines and other immunotherapies. Cancer J. 19(3), 247-262 (2013
11. Chow LM. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am. Soc. Clin. Oncol. Educ. Book 280-285 (2013
12. Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small cell lung cancer. Ann. Oncol. 24(5), 1170-1179 (2013
13. Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: Ongoing clinical trials. Future Oncol. 10(1), 91-105 (2014
14. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 15, 73(8), 2381-2388 (2013
15. Winter H, van Den Engel NK, Rusan M, et al. Active-specific immunotherapy for non-small cell lung cancer. J. Thorac. Dis. 3(2), 105-114 (2011
16. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive disease small-cell lung cancer: Results from a randomized, double-blind, multicenter Phase 2 trial. Ann. Oncol. 24(1), 75-83 (2013
17. Chang S, Lin X, Higashikubo R. Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy. Oncoimmunology 2(3), e23563 (2013
18. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772 (2001
19. Creelan BC, Antonia SJ. Immunotherapy in LC: B7-bombers and other new developments. Semin. Respir. Crit. Care Med. 34(6), 810-821 (2013
20. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9(5), 377-384 (2009
21. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012
22. Eggermont AMM, Kroemer G, Zitvogel L, et al. Immunotherapy and the concept of a clinical cure. Eur. J. Cancer 49, 2965-2967 (2013
23. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell LC: Results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012
24. Zatloukal P, Heo DS, Park K, et al. Randomized Phase II clinical trial comparing tremelimumab (CP-675, 206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) J. Clin. Oncol. 30(17), 2046-2054 (2012
25. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
26. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010
27. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
28. Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J. Clin. Oncol. 31(Suppl.) Abstract 3000 (2013
29. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 31(19), 2396-2403 (2013
30. Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137(9), 1337-1342 (2011
31. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(1), 59-68 (2014
32. Ramlau R, Quoix E, Rolski J, et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J. Thorac. Oncol. 3(7), 735-744 (2008
33. Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled Phase 2B trial. Lancet Oncol. 12(12), 1125-1133 (2011
34. Neninger Vinageras, E, de la Torre A, Osorio Rodríguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol. 26(9), 1452-1458 (2008
35. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J. Clin. Oncol. 23(28), 6854-6864 (2005
36. Alfonso S, Valdes-Zayas A, Santiesteban ER, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-Alum vaccine as switch maintenance therapy in advanced non-small-cell-lung cancer patients. Clin. Cancer Res. 20(14), 3660-3671 (2014
37. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006)
38. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled, Phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Thorac. Oncol. 6(6), 1098-1103 (2011
39. Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebo-controlled Phase II study of single-Agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J. Clin. Oncol. 29(31), 4129-4136 (2011
40. Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann. Oncol. 24(11), 2875-2880 (2013
41. Correale P, Tindara Miano S, Remondo C, et al. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol. Ther. 8(6), 497-502 (2009
42. Ridolfi L, Bertetto O, Santo A, et al. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: Results from a Phase III randomized multicentric trial. Int. J. Oncol. 39(4), 1011-1017 (2011
43. Lissoni P, Brivio F, Fumagalli L, et al. Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 28(2B), 1377-1381 (2008
44. Rijavec E, Genova C, Alama A, et al. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncol. 10(1), 79-90 (2014
45. Mazzoccoli G, Sothern RB, Francavilla M, et al. Hormone and cytokine circadian alteration in non-small cell LC patients. Int. J. Immunopathol. Pharmacol. 25(3), 691-702 (2012
46. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
47. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011
48. Jure-Kunkel M, Masters G, Girit E, et al. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol. Immunother. 62, 1533-1545 (2013
49. Masters G, Barreto L, Girit E, et al. Antitumor activity of cytotoxic T-lymphocyte antigen-4 blockade alone or combined with paclitaxel, etoposide or gemcitabine in murine models. J. Immunother. 32, 994 (2009
50. Patnaik A, Kang SP, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J. Clin. Oncol. 30(Suppl.), Abstract 2512 (2012
51. Spigel Dr, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 2013 ASCO Annual Meeting, J. Clin. Oncol. 31(Suppl.) Abstract 8008 (2013
52. Suzuki H, Owada Y, Watanabe Y, et al. Recent advances in immunotherapy for non-small-cell lung cancer. Hum. Vaccin. Immunother. 10(2), 352-357 (2013
53. GlaxoSmithKline. Press release (2014). www.gsk.com/media/press-releases/2014/update-on-phase- III-clinical-Trial-of-investigational-MAGE-A3
54. Butts C, Murray N, Maksymiuk A, et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005
55. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin. Cancer Res. 5(6), 1319-1323 (1999
56. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 13(6), 555-562 (2006
57. Skachkova OV, Khranovska NM, Gorbach OI, Svergun NM, Sydor RI, Nikulina VV. Immunological markers of anti-Tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer. Exp. Oncol. 35(2), 109-113 (2013
58. Shi S, Wang R, Chen T, et al. Combining antiangiogenic therapies with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models PLoS ONE 8(6), e65757 (2013
59. Yu J, Ren X, Li H, Cao S, Han Y, et al. Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors. Cancer Biother. Radiopharm. 26, 485-494 (2011
60. Tao L, Huang G, Shi S, Chen L. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med. Oncol. 31(1), 777 (2014
61. Hirsh V, Paz-Ares L, Boyer M, et al. Randomized Phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29(19), 2667-2674 (2011
62. Chahinian AP, Goldberg J, Holland JF, Reisman A, Jaffrey IS, Mandel EM. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer. Cancer Treat. Rep. 66(6), 1291-1297 (1982
63. Krauss S, Comas F, Perez C, et al. Treatment of inoperable non-small cell carcinoma of the lung with radiation therapy, with or without levamisole. A randomized trial of the Southeastern Cancer Study group. Am J. Clin. Oncol. 7(5), 405-412 (1984
64. Herskovic A, Bauer M, Seydel HG, et al. Post-operative thoracic irradiation with or without levamisole in non-small cell lung cancer: Results of a Radiation Therapy Oncology Group Study. Int. J. Radiat. Oncol. Biol. Phys. 14(1), 37-42 (1988
65. Roeslin N, Dumont P, Morand G, Wihlm JM, Witz JP. Immunotherapy as an adjuvant to surgery in carcinoma of bronchus. Results in three randomised trials. Eur. J. Cardiothorac. Surg. 3(5), 430-435 (1989
66. Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology 2(7), e25205 (2013
67. Babiak A, Steinhauser M, Götz M, Herbst C, Döhner H, Greiner J. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. Oncol. Rep. 31(1), 384-390 (2014
68. Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. Biomarkers and correlative endpoints for immunotherapy trials. Am. Soc. Clin. Oncol. Educ. Book 287-293 (2013
69. Skachkova OV, Khranovska NM, Gorbach OI, Svergun NM, Sydor RI, Nikulina VV. Immunological markers of anti-Tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer. Exp. Oncol. 35(2), 109-113 (2013
70. Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J. Transl. Med. 9, 214 (2011
71. Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31(19), 2388-2395 (2013
72. Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2(2), 165-175 (2010